Immunotherapy plus targeted drug shows promise in rare aggressive lung cancer
A phase 2 trial reports that camrelizumab plus famitinib produced tumor shrinkage in 42.9 percent of patients with advanced pulmonary ...
A phase 2 trial reports that camrelizumab plus famitinib produced tumor shrinkage in 42.9 percent of patients with advanced pulmonary ...
A retrospective study of 1,979 patients finds that clear cell renal cell carcinoma diagnosed at age 45 or younger shows ...
A pan-cancer analysis of 16 tumor types finds that elevated DNA methylation variability is consistently associated with genomic instability, aggressive ...
A supervised neural network called SuRe outperforms established methods at inferring mutational signature exposures from sparse cancer sequencing data, including ...
A retrospective multicenter study linked class III BRAF alterations in metastatic NSCLC to shorter overall survival and distinct co-mutation patterns ...
A prospective laboratory study that sequenced matched tumor and non-malignant primary cultures from 10 African American men with prostate cancer ...
A retrospective study of 126 bladder cancer patients suggests that ERAS-based perioperative nursing care is associated with gentler postoperative immune ...
A detailed case report from China shows that a rare non-hotspot POLE p.T278K mutation, alongside dual MSH6 frameshift variants and ...
A comprehensive pan-cancer study identifies the ribosome biogenesis enzyme DIMT1 as a prognostic and immune-associated biomarker whose depletion suppresses gastric ...
A 563-patient genomic study from Peking University reveals how KMT2C/D loss-of-function alterations define a hypermutated, MSI-high subgroup of gastric cancer ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine